NEW YORK (GenomeWeb News) - Eli Lilly & Co. said today that it will provide free access to its drug discovery technology to potential collaborators who want to evaluate the therapeutic potential of their compounds.

Under the new program, called the Phenotypic Drug Discovery Initiative, or PD2, Lilly said it will provide free, confidential access to its drug discovery assays via a secure web portal in a move intended to provide "a more convenient point of entry for global external researchers into Lilly's drug discovery and development process."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A European team has launched a four-year study to develop a test to gauge cervical, ovarian, uterine, or aggressive breast cancer risk in women.

As interest in personalized medicine grows, government contractors are entering the field, the Washington Post reports.

In PNAS this week: spatiotemporal study of lncRNA expression, role of extrachromosomal, circular DNAs in yeast, and more.

In PLOS this week: Plasmodium knowlesi population genetics, oral microbiome of infants and children, and more.